Abstract
BackgroundNintedanib is an inhibitor targeting platelet-derived growth factor receptor, fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases that has recently been approved for the treatment of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have